Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 17/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8316576 | 0.93 | OPRD1 (0.60) | OPRD1OPRM1OPRK1MEN1CYP2D6 | |
| SCHEMBL21384863 | 0.91 | OPRD1 (0.61) | OPRD1OPRM1OPRK1MEN1CYP2D6 | |
| SCHEMBL22797697 | 0.83 | OPRD1 (0.48) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5391009 | 0.82 | OPRD1 (0.80) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL10460871 | 0.79 | OPRD1 (0.65) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL2539292 | 0.79 | OPRD1 (0.65) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL8316134 | 0.79 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1 | |
| SCHEMBL2457390 | 0.78 | OPRD1 (0.61) | OPRD1OPRM1OPRK1CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL2310717 | 0.78 | OPRD1 (0.63) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Bromide SCHEMBL7444095 | 0.78 | OPRD1 (0.63) | OPRD1OPRM1OPRK1KCNH2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231551-A1 | COMPOSITIONS AND USES THEREOF | UNIVERSITY OF VIRGINIA | 2020-07-23 | — | — | US | disclosed |
| EP-0536419-B1 | TRICYCLIC TRIAZOLE DERIVATIVES, PRODUCTION AND USE THEREOF | TORAY INDUSTRIES (JP) | 1999-10-13 | — | — | EP | disclosed |
| US-5683998-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS, ANTIPAF AGENTS | TORAY INDUSTRIES, INC. (JP) | 1997-11-04 | — | — | US | disclosed |
| EP-0536419-A1 | TRICYCLIC TRIAZOLE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231551-A1 | COMPOSITIONS AND USES THEREOF | CYP11B2, NQO1, CYP11B1 | OPRD1 3337/4885OPRM1 1786/4885OPRK1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.